Deucravacitinib Patent Expiration
Deucravacitinib is Used for treating moderate-to-severe plaque psoriasis in adults who may benefit from systemic therapy or phototherapy. It was first introduced by Bristol Myers Squibb Co
Deucravacitinib Patents
Given below is the list of patents protecting Deucravacitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sotyktu | US12521390 | Dosage Forms For Tyk2 Inhibitors | Feb 11, 2043 | Bristol |
| Sotyktu | US10000480 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | Nov 07, 2033 | Bristol |
| Sotyktu | US11021475 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | Nov 07, 2033 | Bristol |
| Sotyktu | USRE47929 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | Nov 07, 2033 | Bristol |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Deucravacitinib's patents.
Latest Legal Activities on Deucravacitinib's Patents
Given below is the list recent legal activities going on the following patents of Deucravacitinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Dec, 2025 | US10000480 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Nov, 2024 | US11021475 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Dec, 2021 | US10000480 |
| Patent Issue Date Used in PTA Calculation Critical
| 01 Jun, 2021 | US11021475 |
| Sequence Moved to Public Database | 01 Jun, 2021 | US11021475 |
| Recordation of Patent Grant Mailed Critical
| 01 Jun, 2021 | US11021475 |
| Issue Notification Mailed Critical
| 12 May, 2021 | US11021475 |
| Dispatch to FDC | 04 May, 2021 | US11021475 |
| Letter Accepting Correction of Inventorship Under Rule 1.48 | 03 May, 2021 | US11021475 |
| Application Is Considered Ready for Issue Critical
| 03 May, 2021 | US11021475 |
Deucravacitinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Deucravacitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
